Abstract:Background: Ubrogepant is a prescription medication used to prevent migraine headaches. It is currently available in tablet form. Objective: The goal of this work is to investigate the drug degradation profile of Ubrogepant, as well as to isolate and characterize undiscovered Ubrogepant degradation products by utilizing LC-MS, NMR, and IR spectroscopic analytical techniques. Furthermore, to develop a high resolution, sensitive, stability-indicating analytical approach for detecting and quantifying Ubrogepant degradation products in its pharmaceutical formulation. Method: To identify and quantify the degradation products of Ubrogepant in pharmaceutical products, a novel gradient reverse-phase HPLC (RP-HPLC) technique with a PDA detector was developed by utilizing a C18 stationary phase column. The eluent comprised a mixture of acetonitrile and water with 0.1% v/v ortho-phosphoric acid. To establish the intrinsic stability of Ubrogepant pharmaceutical product, it was stress tested under various degrading circumstances, including water, alkaline, acid hydrolysis, photolytic, oxidative, and thermal. Flash chromatography was used to isolate the two major degradants, and the structures were determined using NMR (1H , 13C, DEPT 135), IR, and LC-MS methods. Results: The Ubrogepant medication was relatively more degradable in alkaline and acidic circumstances, and two unique degradation products were discovered. Based on spectroscopic and chromatographic evidence, it was conclusively demonstrated that these unique compounds were Ubrogepant hydrolysis products. All degradation products have been separated with a resolution greater than 2.0. The peak purity data shown that the Ubrogepant peak in all of the stress samples examined was pure. Under all stress environments, Ubrogepant achieved a minimum mass balance of 95%. The validated developed approach was sensitive enough to quantify Ubrogepant degradation products at 0.03% of the Ubrogepant test concentration. Conclusions: The proposed method was found to be stability-indicating since it fits all of the regulatory authorities' typical requirements. This method is highly efficient for detecting and quantifying impurities in Ubrogepant drug substances and drug products in QC laboratories. Highlights: Two new degradation products of Ubrogepant were successfully extracted and characterized using NMR, IR, and LC-MS spectroscopic methods. The proposed HPLC method can accurately quantify the degradation products of Ubrogepant in pharmaceutical products and is sensitive enough to detect degradation products of Ubrogepant as low as 0.17 µg/mL.

Comprehensive chromatographic analysis of Belumosudil and its degradation products: Development, validation, and In silico toxicity assessment

Unveiling Pretomanid profiling using LC–MS/MS: integrating in-silico toxicity assessment and molecular docking analysis

Insight into in silico prediction and chemical degradation study of osimertinib mesylate by LC-HRMS and NMR: Investigation of a typical case of alkaline pH-mediated oxidative degradation product

QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction

LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin

Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry

Stability Indicating Analytical method, Characterization of Degradation Impurity by UPLC-Q-TOF-MS/MS, and Establishment of Degradation Mechanism of Evodiamine

Assessment of the in vitro metabolic stability of CEP-37440, a selective FAK/ALK inhibitor, in HLMs using fast UPLC–MS/MS method: in silico metabolic lability and DEREK alerts screening

Forced Degradation Products of Olmesartan Medoxomil and their In Vitro Genotoxicity Assessment by Comet Assay using HEK Cells

Identification, Isolation and Characterization of Degradation Products (DPs) in Osimertinib Mesylate (OSM) Tablets by UHPLC-IMS-QTOF-MS, and NMR: Evaluation of Genotoxicity for OSM and DPs

Chromatographic analysis of triple cough therapy; bromhexine, guaiafenesin and salbutamol and pharmaceutical impurity: in-silico toxicity profile of drug impurity

Discerning the stability behaviour of mavacamten availing liquid chromatography‐mass spectrometry and nuclear magnetic resonance spectroscopy: In silico toxicity and mutagenicity prediction of degradation products

Oxidative stress-induced degradation of Brinzolamide: Isolation and in-depth characterization of unique hydroxylamine and oxime degradation products

Green Analytical Approach for HPLC Method Development for Quantification of Sorafenib and Its Pharmacopeia Impurities: LC–MS/MS Characterization and Toxicity Prediction of Stress Degradation Products

Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects

Implementation of green analytical principles to develop and validate the HPLC method for the separation and identification of degradation products of Panobinostat, and its characterization by using LC-QTOF-MS/MS and its in-silico toxicity prediction using ADMET software

Development of a Stability-Indicating Purity Method for Ubrogepant through Stress Degradation Analysis, Extraction, and Characterization of Unidentified Degradation Products Using Flash Chromatography, NMR, IR, and LC-MS

Impurity profiling, chiral analysis, uhplc method development and validation of pharmaceutical compounds

Green quality by design HPLC approach for the simultaneous determination of Bilastine and Montelukast

Drug Degradation Prediction, In Silico Toxicity Assessment and Development of Stability-Indicating, Quality by Design Enabled UFLC Method for Sacubitril-Valsartan